1. Home
  2. CTNM vs BTCS Comparison

CTNM vs BTCS Comparison

Compare CTNM & BTCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • BTCS
  • Stock Information
  • Founded
  • CTNM 2009
  • BTCS 2008
  • Country
  • CTNM United States
  • BTCS United States
  • Employees
  • CTNM N/A
  • BTCS N/A
  • Industry
  • CTNM
  • BTCS Finance: Consumer Services
  • Sector
  • CTNM
  • BTCS Finance
  • Exchange
  • CTNM Nasdaq
  • BTCS Nasdaq
  • Market Cap
  • CTNM 248.7M
  • BTCS 209.0M
  • IPO Year
  • CTNM 2024
  • BTCS N/A
  • Fundamental
  • Price
  • CTNM $12.36
  • BTCS $4.79
  • Analyst Decision
  • CTNM Strong Buy
  • BTCS Strong Buy
  • Analyst Count
  • CTNM 4
  • BTCS 1
  • Target Price
  • CTNM $22.75
  • BTCS $7.00
  • AVG Volume (30 Days)
  • CTNM 278.0K
  • BTCS 3.0M
  • Earning Date
  • CTNM 11-05-2025
  • BTCS 11-12-2025
  • Dividend Yield
  • CTNM N/A
  • BTCS N/A
  • EPS Growth
  • CTNM N/A
  • BTCS N/A
  • EPS
  • CTNM N/A
  • BTCS N/A
  • Revenue
  • CTNM N/A
  • BTCS $7,522,073.00
  • Revenue This Year
  • CTNM N/A
  • BTCS $160.41
  • Revenue Next Year
  • CTNM N/A
  • BTCS $46.15
  • P/E Ratio
  • CTNM N/A
  • BTCS N/A
  • Revenue Growth
  • CTNM N/A
  • BTCS 354.52
  • 52 Week Low
  • CTNM $3.35
  • BTCS $1.05
  • 52 Week High
  • CTNM $20.30
  • BTCS $8.49
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 73.06
  • BTCS 57.61
  • Support Level
  • CTNM $10.30
  • BTCS $4.14
  • Resistance Level
  • CTNM $13.26
  • BTCS $4.58
  • Average True Range (ATR)
  • CTNM 1.04
  • BTCS 0.27
  • MACD
  • CTNM 0.03
  • BTCS 0.03
  • Stochastic Oscillator
  • CTNM 77.13
  • BTCS 98.85

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About BTCS BTCS Inc.

BTCS Inc is engaged in the business of hosting an online e-commerce marketplace where consumers can purchase merchandise using Digital Assets, including bitcoin. The company focuses on blockchain and Digital Asset ecosystems. The firm operates a beta e-commerce marketplace, which accepts a range of digital currencies, has designed a beta secure digital currency storage solution BTCS Wallet. The Company's blockchain infrastructure operations include two primary revenue-generating activities: Ethereum block building and validator node operations.

Share on Social Networks: